Clinical Trials at Retina Northwest
Retina Northwest is committed to fostering cutting edge treatments for retinal diseases through our participation in clinical trials. Brief descriptions of our active clinical trials are listed below. If you are a physician and have questions about any of our trials, or if you would like to refer a patient to our care, please contact our Clinical Research department at 503-274-2121.
Age-Related Macular Degeneration (AMD)
Novartis (CLNP023E12201) Phase 2 (Wet and Dry AMD)
Principal Investigator: Paul Tlucek, MD
Study Coordinator:
Active, Enrollment Closed
A randomized, participant and investigator masked, placebo-controlled, multicenter, proof-of-concept study to assess the safety and efficacy of LNP023 (Iptacopan) in patients with early and intermediate Age-Related Macular Degeneration.
Atrophic (“Dry”)
ReNEW (SPIAM-301) Phase 3 (Dry AMD)
Principal Investigator: Michael Lee, MD
Study Coordinator:
Active, Currently Enrolling
A randomized, double-masked, placebo-controlled clinical trial to evaluate the efficacy, safety, and pharmacokinetics of subcutaneous injections of Elamipretide in subjects who have Dry Age-Related Macular Degeneration.
Sienna (R3918-AMD-2326) Phase 3 (Dry AMD)
Principal Investigator: Michael Lee, MD
Study Coordinator:
Activation Stage – Screening Not Yet Open
A multicenter, randomized, double-masked, placebo-controlled study of the efficacy, safety, and tolerability of subcutaneously administered Pozelimab in combination with Cemdisiran or Cemdisiran alone in participants with geographic atrophy secondary to Age-Related Macular Degeneration. (GA secondary to Dry AMD)
Exudative (“Wet”)
Atmosphere (RGX-314-2104) Phase 2b/3 (Wet AMD)
Principal Investigator: Apurva Patel, MD
Study Coordinator:
Active, Currently Enrolling
A randomized, partially masked, controlled, clinical study to evaluate the efficacy and safety of RGX-314 gene therapy in participants with Neovascular Age-Related Macular Degeneration (Wet AMD).
Atmosphere (RGX-314-5101) Phase 2 (Wet AMD)
Principal Investigator: Apurva Patel, MD
Study Coordinator:
Active, Currently Enrolling
A long-term follow-up study to evaluate the safety and efficacy of RGX-314 following subretinal administration in participants with Neovascular Age-related Macular Degeneration and fellow eye treatment substudy.
Daybreak (KS301P109) Phase 3 (Wet AMD)
Principal Investigator: Apurva Patel, MD
Study Coordinator:
Active, Currently Enrolling
A prospective, randomized, double-masked, active comparator-controlled, multi-center, three-arm study to evaluate the efficacy and safety of intravitreal Tarcocimab Tedromer and Tabirafusp Tedromer compared with intravitreal Aflibercept in participants with Neovascular Age-related Macular Degeneration (Wet AMD).
Portal (GR40549) Phase 3 (Wet AMD)
Principal Investigator: Paul Tlucek, MD
Study Coordinator:
Active, Enrollment Closed
A multicenter, open-label extension study to evaluate the long term safety and tolerability of the port delivery system with Tanibizumab in patients with Neovascular Age-related Macular Degeneration (Wet AMD).
Diabetic Eye Diseases
Diabetic Retinopathy
Brunello (EYE-RES-102) Phase 2/3 (DME)
Principal Investigator: Apurva Patel, MD
Study Coordinator:
Active, Currently Enrolling
A randomized, double-masked, multi-center, 3-arm pivotal study to evaluate the efficacy and safety of intravitreal, EYE103, compared with intravitreal Lucentis (Ranibizumab) (0.5mg) in participants with Diabetic Macular Edema (DME).
Pagoda (GR40550) Phase 3 (DME)
Principal Investigator: Paul Tlucek, MD
Study Coordinator:
Active, Enrollment Closed
A multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema (DME).
Principal Investigator: Paul Tlucek MD
Study Coordinator: Ashley Adamo
Active, Currently Enrolling
A Pilot Study evaluating Photobiomodulation Therapy for Diabetic Macular Edema (Protocol AE).
Principal Investigator: Mark Peters, MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Enrollment Closed
A Comparative Effectiveness Study of Intravitrela Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema Extension Study
KS301P104 (DME)
Principal Investigator: Apurva Patel, MD
Study Coordinator: Brian Heimdahl
Active, Enrollment Closed
Gleam: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
Uveitis
Non-infectious Uveitis
Clarity (PVT-221-303) Phase 3 (Uveitis)
Principal Investigator: Harpal Sandhu, MD
Study Coordinator:
Active, Currently Enrolling
A randomized, double-masked, placebo-controlled study to investigate the safety and efficacy of oral Brepocitinib in adults with active, non-infectious Intermediate-, Posterior-,and Panuveitis.
GR41986 (CVO)
Principal Investigator: Apurva Patel, MD
Study Coordinator: Brian Heimdahl
Active, Enrollment Closed
Comino: A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion.
